A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Brain Contusion

In brief

The primary objective is to determine if BIIB093 reduces brain contusion expansion by Hour 96 when compared to placebo. The secondary objectives are to evaluate the effects of BIIB093 on acute neurologic status, functional outcomes, and treatment requirements, to further differentiate the mechanism of action of BIIB093 on contusion expansion by examining differential effects on hematoma and edema expansion, and to determine if BIIB093 improves survival at Day 90 when compared to placebo.

Key facts

Study ID
NCT03954041
Run by
Remedy Pharmaceuticals, Inc.
People needed
92
Starts
2019-10-06
Expected to finish
2023-06-27
Last updated by the study team
2024-11-27

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.